Post Profile






Exelixis and Pfizer drugs face off in kidney cancer

COPENHAGEN (Reuters) - Exelixis' drug Cabometyx beat Pfizer's Sutent in a clinical study in metastatic kidney cancer, suggesting it has the potential to become a first-line treatment, researchers said on Monday.
read more

share

Related Posts


Pazopanib Shows Better Quality-of-Life in Advanced Kidney Cancer

Health : Newswise Medical News

An international study led by Dana-Farber scientists found that the oral targeted drugs pazopanib (Votrient) and sunitinib (Sutent), approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability.

Mayo Clinic Researchers Identify Potential Immunotherapy Drug Combination for Targeting Advanced and Metastatic Cancers

Health : Newswise Medical News

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, publi...

Success Of Pfizer Pancreatic Cancer Drug Stops Trial

Health : Medical News Today

Global drug company Pfizer Inc announced yesterday, 12 March, that a phase 3 clinical trial of its pancreatic cancer drug Sutent (sunitinib malate) stopped early because the drug showed significant benefits in patients. Sutent is de...

Immunotherapy drug a 'gamechanger' for head and neck cancer

Health : The Guardian: Health

Nivolumab found to extend lives of relapsed patients who had run out of therapy options An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untrea...

No silver lining in failed Bristol cancer drug trial

Health : Reuters: Health

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closel...

Comments


Copyright © 2016 Regator, LLC